Optimizing use of tumor necrosis factor inhibitors in the management of immune-mediated inflammatory diseases

Journal of Rheumatology

Volumn 37, Issue SUPPL. 85, 2010, Pages 40-52

  Bressler, Brian ^a   Haraoui, Boulos ^b,c   Keystone, Edward ^d,e,f   Sette, Alessandro ^g  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c NOTRE DAME HOSPITAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e Rebecca MacDonald Centre for Arthritis and Autoimmune Disease   (Canada)

^f Division of Advanced Therapeutics in Arthritis   (Canada)

^g LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

Anti tumor necrosis factor; Disease modifying antirheumatic drugs; Immune mediated inflammatory diseases

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; ANTIINFLAMMATORY AGENT; AUTACOID; TUMOR NECROSIS FACTOR ALPHA;

ANKYLOSING SPONDYLITIS; BACTEREMIA; CLINICAL TRIAL; CROHN DISEASE; DEMYELINATING DISEASE; DRUG COST; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; ENTERITIS; HERPES ZOSTER; HUMAN; IMMUNE MEDIATED INFLAMMATORY DISEASE; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INCIDENCE; INFLAMMATORY DISEASE; LISTERIOSIS; LOW DRUG DOSE; LUPUS VULGARIS; MENINGITIS; MYCOSIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; T CELL LYMPHOMA; THERAPY EFFECT; TREATMENT RESPONSE; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; VASCULITIS; DRUG ANTAGONISM; DRUG SUBSTITUTION; IMMUNOLOGY; INFLAMMATION; METABOLISM; PATIENT COMPLIANCE; PATIENT SELECTION; RISK ASSESSMENT; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS; DRUG SUBSTITUTION; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MEDICATION ADHERENCE; PATIENT SELECTION; RISK ASSESSMENT; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77957865910     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.091464     Document Type: Review

References (106)

1. Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ. British Society for Rheumatology Biologics Register. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 2007;56:13-20.
2. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.
3. Pan SM, Dehler S, Ciurea A, Ziswiler HR, Gabay C, Finckh A, et al. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum 2009;61:560-8.
4. Duclos M, Gossec L, Ruyssen-Witrand A, Salliot C, Luc M, Guignard S, et al. Retention rates of TNF blockers in daily practice in 770 rheumatic patients. J Rheumatol 2006;33:2433-9. (Pubitemid 46067822)
5. Pincus T, Yazici Y, van Vollenhoven R. Why are only 50% of courses of anti-tumor necrosis factor agents continued for only 2 years in some settings? Need for longterm observations in standard care to complement clinical trials. J Rheumatol 2006;33:2372-5. (Pubitemid 46067813)
6. Flendrie M, Creemers MCW, Welsing PMJ, den Broeder AA, van Riel PLCM. Survival during treatment with tumor necrosis factor blocking agents in rheumatoid arthritis. Ann Rheum Dis 2003;62 Suppl II:ii30-ii33. (Pubitemid 37323597)
7. Zink A, Listing J, Kary S, Ramlau P, Stoyanova-Scholz M, Babinsky K, et al. Treatment continuation in patients receiving biological agents or conventional DMARD therapy. Ann Rheum Dis 2005;64:1274-9. (Pubitemid 41206242)
8. Ostergaard M, Unkerskov J, Linde L, Krogh NS, Ravn T, Ringsdal VS, et al. Low remission rates but long drug survival in rheumatoid arthritis patients treated with infliximab or etanercept: results from the nationwide Danish DANBIO database. Scand J Rheumatol 2007;36:151-4. (Pubitemid 46685757)
9. Stern R, Wolfe F. Infliximab dose and clinical status: results of 2 studies in 1642 patients with rheumatoid arthritis. J Rheumatol 2004;31:1538-45. (Pubitemid 39006634)
10. Weinblatt M, Genovese M, Bathon J, Kremer J, Fleischmann R, Schiff M, et al. Safety and efficacy of etanercept (Enbrel®) treatment in North American patients with early and long-standing rheumatoid arthritis: 10 years of clinical experience [abstract]. Arthritis Rheum 2008;58 Suppl:S540.
11. Weinblatt ME, Keystone EC, Furst DE, Kavanaugh AF, Perez JL, Segurado OG. Change over time in the safety, efficacy, and remission profiles of patients with rheumatoid arthritis receiving adalimumab for up to 7 years [abstract]. Arthritis Rheum 2007;56 Suppl:S163.
12. Cramer J, Rosenheck R, Kirk G, Krol W, Krystal J; VA Naltrexone Study Group 425. Medication compliance feedback and monitoring in a clinical trial: predictors and outcomes. Value Health 2003;6:566-73.
13. Zimmerer T, Siegmund SV, Singer MV. The problems of compliance and adherence, using the example of chronic inflammatory bowel disease. Dtsch Med Wochenschr 2009;134:1417-24.
14. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-97.
15. Rubin G, Hungin AP, Chinn D, Dwarakanath AD, Green L, Bates J. Long-term aminosalicylate therapy is under-used in patients with ulcerative colitis: a cross-sectional survey. Aliment Pharmacol Ther 2002;16:1889-93. (Pubitemid 35253004)
16. Kane SV, Cohen RD, Aikens JE, Hanauer SB. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol 2001;96:2929-33.
17. Bernal I, Domènech E, Garcia-Planella E, Marín L, Mañosa M, Navarro M, et al. Medication-taking behavior in a cohort of patients with inflammatory bowel disease. Dig Dis Sci 2006;51:2165-9.
18. Kane S, Dixon L. Adherence rates with infliximab therapy in Crohn's disease. Aliment Pharmacol Ther 2006;24:1099-103. (Pubitemid 44386535)
19. Tang B, Rahman M, Waters HC, Callegari P. Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis. Clin Ther 2008;30:1375-84.
20. Saad AA, Ashcroft DM, Watson KD, Hyrich KL, Noyce PR, Symmons DP; British Society for Rheumatology Biologics Register. Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. Arthritis Res Ther 2009;11:R52.
21. Ediger JP, Walker JR, Graff L, Lix L, Clara I, Rawsthorne P, et al. Predictors of medication adherence in inflammatory bowel disease. Am J Gastroenterol 2007;102:1417-26.
22. Curkendall S, Patel V, Gleeson M, Campbell RS, Zagari M, Dubois R. Compliance with biologic therapies for rheumatoid arthritis: do patient out-of-pocket payments matter? Arthritis Rheum 2008;59:1519-26.
23. Loftus EV Jr. A practical perspective on ulcerative colitis: patients' needs from aminosalicylate therapies. Inflamm Bowel Dis 2006;12:1107-13.
24. Kane SV. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2006;23:577-85.
25. Sewitch MJ, Abrahamowicz M, Barkun A, Bitton A, Wild GE, Cohen A, et al. Patient nonadherence to medication in inflammatory bowel disease. Am J Gastroenterol 2003;98:1535-44.
26. Nigro G, Angelini G, Grosso SB, Caula G, Sategna-Guidetti C. Psychiatric predictors of noncompliance in inflammatory bowel disease: psychiatry and compliance. J Clin Gastroenterol 2001;32:66-8.
27. Ockene IS, Hayman LL, Pasternak RC, Schron E, Dunbar-Jacob J. Task force #4 - adherence issues and behavior changes: achieving a long-term solution. 33rd Bethesda Conference. J Am Coll Cardiol 2002;40:630-40.
28. Horne R, Parham R, Driscoll R, Robinson A. Patients' attitudes to medicines and adherence to maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis 2009;15:837-44.
29. Anderson PJ. Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles. Semin Arthritis Rheum 2005;34 Suppl 1:19-22.
30. van der Laken CJ, Voskuyl AE, Roos JC, Stigter van Walsum M, de Groot ER, Wolbink G, et al. Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and nonresponders to therapy for rheumatoid arthritis. Ann Rheum Dis 2007;66:253-6.
31. Haraoui B, Cameron L, Ouellet M, White B. Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response. J Rheumatol 2006;33:31-6.
32. van de Putte LB, Atkins C, Malaise M, Sany J, Russell AS, van Riel PL, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004;63:508-16.
33. Wolbink GJ, Vis M, Lems W, Voskuyl AE, de Groot E, Nurmohamed MT, et al. Development of anti-infliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:711-5.
34. Centocor, Inc. Remicade® [infliximab] Product monograph 2009 [Internet. Accessed 14 Jan 2010]. Available from: http://www.scheringplough.ca/ english/our%20products/products/default.asp?s=1
35. Bender NK, Heilig CE, Dröll B, Wohlgemuth J, Armbruster FP, Heilig B. Immunogenicity, efficacy and adverse events of adalimumab in RA patients. Rheumatol Int 2007;27:269-74.
36. Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007;66:921-6.
37. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48:35-45.
38. Abbott Laboratories Ltd. Humira® [adalimumab] Product Monograph 2009 [Internet. Accessed 14 Jan 2010]. Available from: http://www.abbott.ca/content/ en-CA/20.10.210:210/product/Product-Profile-0210.htm
39. Dore RK, Mathews S, Schechtman J, Surbeck W, Mandel D, Patel A, et al. The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis. Clin Exp Rheumatol 2007;25:40-6.
40. Keystone EC, Schiff MH, Kremer JM, Kafka S, Lovy M, DeVries T, et al. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2004;50:353-63.
41. Klareskog L, Wajdula J, Baker P, Fatenejad S. Low and transient auto- and anti-etanercept antibody formation has no measurable impact on clinical outcomes during 5 years of etanercept (Enbrel®) treatment in patients with rheumatoid arthritis [abstract]. Ann Rheum Dis 2006;65 Suppl II:325.
42. Fradkin AH, Carpenter JF, Randolph TW. Immunogenicity of aggregates of recombinant human growth hormone in mouse models. J Pharm Sci 2009;98:3247-64.
43. Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum 2006;54:3782-9.
44. Perdriger A. Infliximab in the treatment of rheumatoid arthritis. Biologics 2009;3:183-91.
45. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63.
46. Chan A, Filer A, Parsonage G, Kollnberger S, Gundle R, Buckley CD, et al. Mediation of the proinflammatory cytokine response in rheumatoid arthritis and spondylarthritis by interactions between fibroblast-like synoviocytes and natural killer cells. Arthritis Rheum 2008;58:707-17.
47. Gracie JA, Forsey RJ, Chan WL, Gilmour A, Leung BP, Greer MR, et al. A proinflammatory role for IL-18 in rheumatoid arthritis. J Clin Invest 1999;104:1393-401.
48. Kary S, Burmester GR. Anakinra: the first interleukin-1 inhibitor in the treatment of rheumatoid arthritis. Int J Clin Pract 2003;57:231-4.
49. Plushner SL. Tocilizumab: an interleukin-6 receptor inhibitor for the treatment of rheumatoid arthritis. Ann Pharmacother 2008;42:1660-8.
50. Hyrich KL, Watson KD, Silman AJ, Symmons DP; British Society for Rheumatology Biologics Register. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology 2006;45:1558-65.
51. Kristensen LE, Kapetanovic MC, Gülfe A, Söderlin M, Saxne T, Geborek P. Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology 2008;47:495-9.
52. Gulfe A, Kristensen LE, Geborek P. Six and 12 weeks treatment response predicts continuation of tumor necrosis factor blockade in rheumatoid arthritis: an observational cohort study from southern Sweden. J Rheumatol 2009;36:517-21.
53. Agarwal SK, Glass RJ, Shadick NA, Coblyn JS, Anderson RJ, Maher NE, et al. Predictors of discontinuation of tumor necrosis factor inhibitors in patients with rheumatoid arthritis. J Rheumatol 2008;35:1737-44.
54. Keystone EC, Haraoui B, Bykerk VP. Role of adalimumab in the treatment of early rheumatoid arthritis. Clin Exp Rheumatol 2003;21 Suppl 31:S198-9.
55. Keystone EC, Haraoui B, Bykerk VP. Role of infliximab in the treatment of early rheumatoid arthritis. Clin Exp Rheumatol 2003;21 Suppl 31:S200-2.
56. Buch MH, Seto Y, Bingham SJ, Bejarano V, Bryer D, White J, et al. C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept. Arthritis Rheum 2005;52:42-8.
57. Maser EA, Villela R, Silverberg MS, Greenberg GR. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006;4:1248-54.
58. Rudwaleit M, Claudepierre P, Wordsworth P, Cortina EL, Sieper J, Kron M, et al. Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. J Rheumatol 2009;36:801-8.
59. Miceli-Richard C, Comets E, Verstuyft C, Tamouza R, Loiseau P, Ravaud P, et al. A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis. Ann Rheum Dis 2008;67:478-84.
60. Padyukov L, Lampa J, Heimbürger M, Ernestam S, Cederholm T, Lundkvist I, et al. Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis. Ann Rheum Dis 2003;62:526-9.
61. Hlavaty T, Pierik M, Henckaerts L, Ferrante M, Joossens S, van Schuerbeek N, et al. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease. Aliment Pharmacol Ther 2005;22:613-26.
62. Oliveira RDR, Fontana V, Junta CM, et al. Differential gene expression of responders and nonresponders to anti-TNF-alpha therapy in rheumatoid arthritis. Ann Rheum Dis 2009;68 Suppl 3:430.
63. Gomez-Reino JJ, Carmona L, BIOBADASER Group. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther 2006;8:R29.
64. Nalysnyk L, Xu Y, Williams K, Sharma S, Villanueva I, Sallerin V, et al. Treatment of rheumatoid arthritis after failure of TNF antagonists: a systematic review and meta-analysis. Ann Rheum Dis 2008;67 Suppl II:326.
65. Bombardieri S, Ruiz AA, Fardellone P, Geusens P, McKenna F, Unnebrink K, et al. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatology 2007;46:1191-9.
66. Villeneuve E, Haraoui B. Switching between TNF-alpha inhibitors in the treatment of rheumatoid arthritis. Int J Adv Rheumatol 2006;4:2-8.
67. Allez M, Vermeire S, Mozziconacci N, Michetti P, Laharie D, Louis E, et al. The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of 2 other anti-TNF antibodies. Aliment Pharmacol Ther 2010;31:92-101.
68. Smolen J, Kay J, Doyle MK, Landewé R, Matteson EL, Wollenhaupt J, et al. Golimumab, a new human anti-TNF-alpha monoclonal antibody, subcutaneously administered every 4 weeks in patients with active rheumatoid arthritis who were previously treated with anti-TNF-alpha agent(s): results of the randomized, double-blind, placebo-controlled study. Ann Rheum Dis 2008;67 Suppl II:50.
69. Hyrich KL. What have biologic registers taught us? Rheumatoid Arthritis National Grand Rounds 2008;2:1-6.
70. Silman A, Symmons D, Scott DG, Griffiths I. British Society for Rheumatology Biologics Register. Ann Rheum Dis 2003;62 Suppl 2:ii28-9.
71. Askling J, Fored CM, Geborek P, Jacobsson LT, van Vollenhoven R, Feltelius N, et al. Swedish registers to examine drug safety and clinical issues in RA. Ann Rheum Dis 2006;65:707-12.
72. Kroesen S, Widmer AF, Tyndall A, Hasler P. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology 2003;42:617-21.
73. Listing J, Strangfeld A, Kary S, Rau R, von Hinueber U, Stoyanova-Scholz M, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005;52:3403-12.
74. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002;46:2287-93.
75. Dixon WG, Hyrich KL, Watson KD, Lunt M, Symmons DP. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the BSRBR [abstract]. Arthritis Rheum 2008;58 Suppl:s638.
76. Crum NF, Lederman ER, Wallace MR. Infections associated with tumor necrosis factor-alpha antagonists. Medicine (Baltimore) 2005;84:291-302.
77. Greenberg HB, Matsui SM, Holodniy M. Small intestine: infections with common bacterial and viral pathogens. In: Yamada T, Alpers DH, Laine L, Owyang C, Powell DW, editors. Textbook of gastroenterology. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 1999:1530-60.
78. Hamer DH, Gorbach SL. Infectious diarrhea and bacterial food poisoning. In: Feldman M, Friedman LS, Sleisenger MH, editors. Sleisenger and Fordtran's gastrointestinal and liver disease. 7th ed. Philadelphia: WB Saunders Company; 2002:1864-913.
79. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104.
80. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD; BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003;48:2122-7.
81. Anelli MG, Torres DD, Manno C, Scioscia C, Iannone F, Covelli M, et al. Improvement of renal function and disappearance of hepatitis B virus DNA in a patient with rheumatoid arthritis and renal amyloidosis following treatment with infliximab. Arthritis Rheum 2005;52:2519-20.
82. Colbert C, Chavarria A, Berkelhammer C. Fulminant hepatic failure in chronic hepatitis B on withdrawal of corticosteroids, azathioprine and infliximab for Crohn's disease. Inflamm Bowel Dis 2007;13:1453-4.
83. Calabrese LH, Zein N, Vassilopoulos D. Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann Rheum Dis 2004;63 Suppl 2:ii18-ii24.
84. Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 2009;301:737-44.
85. Tsiodras S, Samonis G, Boumpas DT, Kontoyiannis DP. Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clin Proc 2008;83:181-94.
86. De Rycke L, Baeten D, Kruithof E, Van den Bosch F, Veys EM, De Keyser F. The effect of TNF-alpha blockade on the antinuclear antibody profile in patients with chronic arthritis: biological and clinical implications. Lupus 2005;14:931-7.
87. De Rycke L, Baeten D, Kruithof E, Van den Bosch F, Veys EM, De Keyser F. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis. Arthritis Rheum 2005;52:2192-201.
88. Bobbio-Pallavicini F, Alpini C, Caporali R, Avalle S, Bugatti S, Montecucco C. Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. Arthritis Res Ther 2004;6:R264-72.
89. Ramos-Casals M, Brito-Zerón P, Muñoz S, Soria N, Galiana D, Bertolaccini L, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007;86:242-51.
90. Colombel JF, Loftus EV Jr, Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004;126:19-31.
91. Costa MF, Said NR, Zimmermann B. Drug-induced lupus due to anti-tumor necrosis factor alpha agents. Semin Arthritis Rheum 2008;37:381-7.
92. Borg FA, Isenberg DA. Syndromes and complications of interferon therapy. Curr Opin Rheumatol 2007;19:61-6.
93. Caramaschi P, Biasi D, Colombatti M, Pieropan S, Martinelli N, Carletto A, et al. Anti-TNF-alpha therapy in rheumatoid arthritis and autoimmunity. Rheumatol Int 2006;26:209-14.
94. Saint Marcoux B, De Bandt M; CRI (Club Rhumatismes et Inflammation). Vasculitides induced by TNF-alpha antagonists: a study in 39 patients in France. Joint Bone Spine 2006;73:710-3.
95. Harrison MJ, Dixon WG, Watson KD, King Y, Groves R, Hyrich KL, et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2009;68:209-15.
96. Freeman HJ, Flak B. Demyelination-like syndrome in Crohn's disease after infliximab therapy. Can J Gastroenterol 2005;19:313-6.
97. Gupta G, Gelfand JM, Lewis JD. Increased risk for demyelinating diseases in patients with inflammatory bowel disease. Gastroenterology 2005;129:819-26.
98. Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001;44:2862-9.
99. Fleischmann R, Baumgartner SW, Weisman MH, Liu T, White B, Peloso P. Long term safety of etanercept in elderly subjects with rheumatic diseases. Ann Rheum Dis 2006;65:379-84.
100. Al Saieg N, Luzar MJ. Etanercept induced multiple sclerosis and transverse myelitis. J Rheumatol 2006;33:1202-4.
101. Gelfand JM, Berlin J, Van Voorhees A, Margolis DJ. Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. Arch Dermatol 2003;139:1425-9.
102. Paul CF, Ho VC, McGeown C, Christophers E, Schmidtmann B, Guillaume JC, et al. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Invest Dermatol 2003;120:211-6.
103. von Roon AC, Reese G, Teare J, Constantinides V, Darzi AW, Tekkis PP. The risk of cancer in patients with Crohn's disease. Dis Colon Rectum 2007;50:839-55.
104. Franklin J, Lunt M, Bunn D, Symmons D, Silman A. Incidence of lymphoma in a large primary care derived cohort of cases of inflammatory polyarthritis. Ann Rheum Dis 2006;65:617-22.
105. Mackey AC, Green L, Liang LC, Dinndorf P, Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007;44:265-7.
106. Vermeire S, Van Assche G, Rutgeerts P. Serum sickness, encephalitis and other complications of anti-cytokine therapy. Best Pract Res Clin Gastroenterol 2009;23:101-12.